

Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients

NCT07081087

Status RECRUITING
Sponsor Weizmann Institute of Science
Enrollment 1,500 participants

Key Eligibility Criteria

Inclusion (5)

- Patients aged 18 and up with suspected/confirmed MDS cases referred to BM evaluation either for diagnosis or risk assessment due to cytopenia
- Platelets $\leq 150 \times 10^9/L$ or
- Absolute neutrophil count $\leq 1.8 \times 10^9/L$ or
- Hemoglobin (Hgb) ≤ 13 g/dL (males) and ≤ 12 g/dL (female) and
- For both sexes, no evidence of Iron, folic acid, or B12 deficiency

Exclusion (5)

- Women who are pregnant
- Previous diagnosis of leukemia; AML, MPN, ALL, CLL, MGUS/MM or any other gammopathy
- Lymphocytes $> 5000/uL$
- Patients who are on disease-related therapy are excluded, unless they are treated with Erythropoietin or Prednisone. See Appendix 2 for the list of excluded treatments.
- Patients who have undergone a bone marrow transplant.

Locations (2 total)

University of California San Diego, San Diego, California, United States
University of Miami, Miami, Florida, United States

<https://clinicaltrials.gov/study/NCT07081087>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.